Appropriate Use of Tocilizumab in COVID-19: Early Use is Beneficial.
Lütfiye Nilsun AltunalMehtap AydınAyşe Serra ÖzelGülsüm ÇamPublished in: Infectious diseases & clinical microbiology (2022)
The number of comorbidities, high levels of CRP, initiation of TCZ in the ICU and not receiving the additional dose of TCZ were significant risk factors for fatality among patients with COVID-19 who received TCZ. Early initiation of TCZ when cytokine storm is suspected is appropriate for the prevention of fatality.